Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
CTIBIOTECH is a biomedical R&D services company founded in 2009, headquartered in Lyon, France, with an office in Philadelphia, USA. According to the website, its core offering is not general SaaS or enterprise software, but advanced human tissue, cell models, and preclinical testing services for pharmaceutical, cosmetics, medical device, vaccine, and research organizations. Its goal is to replace animal testing with models that more closely resemble the human body.
The company’s key capabilities include the development of 3D human tissue and cell models, applications of stem cell and 3D bioprinting technologies, innovative skin tissue testing, drug screening, toxicity testing, preclinical evaluation, and CRO services. Oncology is one of its standout areas: the website mentions capabilities such as cancer biopsy collection, cell production, cancer organoids, single-cell/cell-cluster models, and 3D-printed short- and long-term screening systems, which can be used to test chemotherapy combinations, dosages, and new therapies. CTIBIOTECH can also provide human-derived cells and tissues for customers to conduct research in their own laboratories.
The website does not disclose standard packages, subscription pricing, or an online purchasing process. Its project workflow is closer to a customized service model: consultation and requirements definition first, followed by solution design, timeline and resource planning, laboratory testing and monitoring, and finally the delivery of an actionable report with follow-up support. As a result, procurement is most likely based on project-based quotations, making it suitable for institutional clients with clearly defined experimental goals.
Its strengths lie in its strong expertise in human-derived models and broad application coverage across cosmetics, drugs, vaccines, medical devices, and cancer screening. Its French laboratory is ISO 9001:2015 certified, and the company states that it is authorized to handle human tissue. Its services have been used in more than 30 countries. The downside, from an enterprise software perspective, is that the website does not disclose SaaS capabilities such as a cloud platform, permission-based collaboration, APIs, third-party integrations, data dashboards, or self-service configuration. It also lacks information on pricing, delivery timelines, and sample data.
CTIBIOTECH is suitable for pharmaceutical and biotechnology companies, cosmetics R&D teams, hospitals, universities, cancer centers, and research teams seeking human-derived models as alternatives to animal testing. The website does not specify accessibility from China, nor does it show information about a local China office or compliance support. Potential customers are advised to confirm sample shipping, data delivery, contract terms, and cross-border collaboration requirements by email.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on ctibiotech.com official site.
ctibiotech.com is an France Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach ctibiotech.com directly.